Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Arcus Biosciences ( (RCUS) ) is now available.
On April 20, 2026, Arcus Biosciences said it will discontinue the Phase 3 STAR-121 trial, run with Gilead Sciences, after an independent committee found the domvanalimab plus zimberelimab and chemotherapy regimen futile versus pembrolizumab plus chemotherapy in first-line metastatic non-small cell lung cancer. An exploratory arm showed zimberelimab plus chemotherapy delivered overall survival in line with pembrolizumab plus chemotherapy, and both STAR-121 and the Phase 2 EDGE-Lung study will be stopped as Gilead works with investigators on next steps for enrolled patients.
Arcus also reported that Gilead’s period for exercising broader option rights under their 2020 collaboration will end on July 14, 2026, after Gilead chose not to make an option continuation payment, relinquishing access to several early-stage programs while retaining time-limited options to assets such as AB801, AB598, AB102 and an investigational TNF inhibitor. Arcus will keep full rights to its casdatifan program outside territories already licensed to Taiho, underscoring a shift in the partners’ collaboration scope that could reshape Arcus’s future partnering and development strategy.
The most recent analyst rating on (RCUS) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Arcus Biosciences stock, see the RCUS Stock Forecast page.
Spark’s Take on RCUS Stock
According to Spark, TipRanks’ AI Analyst, RCUS is a Neutral.
The score is held back primarily by weak financial performance driven by large losses and heavy cash burn. Offsetting this, the earnings call pointed to strong clinical progress and a sizeable cash runway, while technicals show an improved price trend but mixed momentum; valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on RCUS stock, click here.
More about Arcus Biosciences
Arcus Biosciences, Inc. is a biopharmaceutical company focused on developing immuno-oncology therapies, including monoclonal antibodies and small molecules, targeting pathways such as TIGIT and PD-1 for the treatment of cancers like metastatic non-small cell lung cancer. The company operates through collaborations with larger pharmaceutical partners while also retaining rights to key programs and regional licensing arrangements.
Average Trading Volume: 1,101,514
Technical Sentiment Signal: Buy
Current Market Cap: $2.97B
See more insights into RCUS stock on TipRanks’ Stock Analysis page.